Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Benzinga Newsdesk www.benzinga.com Negative 88.1%

Neg 88.1% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.